InvestorsHub Logo
Followers 10
Posts 1254
Boards Moderated 0
Alias Born 07/20/2020

Re: None

Wednesday, 12/07/2022 3:47:34 PM

Wednesday, December 07, 2022 3:47:34 PM

Post# of 651522
ARDS $1 --Phase 3 data next week --Market cap $21 million

Closed enrollment in the Company’s Phase 3 study evaluating AR-301 for the treatment of Ventilator Associated Pneumonia (VAP). Aridis expects to report top-line data from this study in December 2022.
Join InvestorsHub

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.